The period marks a shift toward serology-driven recognition of autoimmune processes in liver disease, with emphasis on autoantibody signatures and humoral immune mechanisms that distinguish autoimmune hepatitis, autoimmune cholestatic diseases, and related conditions. Methodological focus centers on antibody detection, serologic profiling, and correlating profiles with clinical phenotypes to guide diagnosis and classification.